




Aerie Pharmaceuticals
Investor Relations Department
135 US Highway 206, Suite 15
Bedminster, NJ 07921
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: AERI

Last Trade:	55.90
Trade Time:	4:00 PM ET May 26, 2017
Change:	1.65  (+3.04%)
Day Range	54.30 - 57.90
52-Week Range	16.41 - 59.50
Volume	2,791,613

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, which results in irreversible vision loss and potentially blindness. Patients may suffer the adverse effects of glaucoma across a wide range of IOP levels. Our product candidates, Rhopressa™ (netarsudi... [\(more\)](#))

Stock Performance



Press Releases [\[View all \]](#)

- May 26, 2017
[Aerie Pharmaceuticals Raises \\$125 Million in ATM Sales and Upsized Follow-On Offering](#)
- May 25, 2017
[Aerie Pharmaceuticals Announces Public Offering of Common Stock](#)
- May 24, 2017
[Aerie Pharmaceuticals Reports Positive Roclatan™ \(netarsudil/latanoprost ophthalmic solution\) 0.02%/0.005% Phase 3 Topline Efficacy Results](#)
- May 16, 2017
[Aerie Pharmaceuticals Announces New Hires](#)
- May 15, 2017
[Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa™ \(netarsudil ophthalmic solution\) 0.02%](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 9, 2017
[Annual Report \(10-K\)](#)
- Apr 27, 2017
[Proxy Statement \(DEF 14A\)](#)
- May 3, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016
[Quarterly Report \(10-Q\)](#)